Putting the puzzle together: SGLT2 inhibitors from prevention to treatment of heart failure

Article Biochemistry & Molecular Biology

The SGLT2 inhibitor empagliflozin in patients hospitalized for acute heart failure: a multinational randomized trial

Adriaan A. Voors et al.

Summary: The sodium-glucose cotransporter 2 inhibitor empagliflozin improves clinical outcomes in patients hospitalized for acute heart failure, regardless of ejection fraction or the presence of diabetes.

NATURE MEDICINE (2022)

添加到收藏夹

Review Cardiac & Cardiovascular Systems

Acute Decompensated Heart Failure in the Setting of Acute Coronary Syndrome

Josephine Harrington et al.

Summary: Acute coronary syndrome (ACS) often leads to heart failure (HF), and older, female patients with preexisting heart disease, type 2 diabetes, hypertension, and/or kidney disease are at the highest risk for acute decompensated HF in the setting of ACS (ACS-HF). The presence of ACS-HF is strongly associated with higher mortality and more frequent readmissions for HF. Low implementation of guideline-directed medical therapy has posed challenges in caring for this high-risk population. Improved utilization of current therapies and further research on managing ACS-HF are urgently needed to improve outcomes in this vulnerable population.

JACC-HEART FAILURE (2022)

添加到收藏夹

Article Cardiac & Cardiovascular Systems

Empagliflozin in acute myocardial infarction: the EMMY trial

Dirk von Lewinski et al.

Summary: This study investigated the effects of empagliflozin on patients following acute myocardial infarction, showing significant reductions in NT-proBNP and improvements in echocardiographic parameters.

EUROPEAN HEART JOURNAL (2022)

添加到收藏夹

Article Medicine, General & Internal

Sotagliflozin in Patients with Diabetes and Recent Worsening Heart Failure

Deepak L. Bhatt et al.

Summary: In patients with diabetes and recent worsening heart failure, treatment with sotagliflozin significantly reduced the total number of deaths from cardiovascular causes and hospitalizations and urgent visits for heart failure compared to placebo, regardless of the timing of administration.

NEW ENGLAND JOURNAL OF MEDICINE (2021)

添加到收藏夹

Article Medicine, General & Internal

Angiotensin Receptor-Neprilysin Inhibition in Acute Myocardial Infarction

M. A. ap Pfeffer et al.

Summary: Among patients with acute myocardial infarction, the use of Sacubitril-Valsartan did not significantly reduce the incidence of death from cardiovascular causes or incident heart failure compared to ramipril.

NEW ENGLAND JOURNAL OF MEDICINE (2021)

添加到收藏夹

Article Cardiac & Cardiovascular Systems

Prognostic Importance of NT-proBNP and Effect of Empagliflozin in the EMPEROR-Reduced Trial

Jr James L. Januzzi et al.

Summary: This study found that empagliflozin treatment reduced the risk of heart failure or renal events regardless of baseline NT-proBNP concentration in patients with heart failure.

JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2021)

添加到收藏夹

Article Medicine, General & Internal

Empagliflozin in Heart Failure with a Preserved Ejection Fraction

Stefan D. Anker et al.

Summary: Empagliflozin reduces the risk of cardiovascular death or hospitalization for heart failure in patients with heart failure and a preserved ejection fraction, regardless of the presence or absence of diabetes.

NEW ENGLAND JOURNAL OF MEDICINE (2021)

添加到收藏夹

Article Medicine, General & Internal